updated 5/10/2010 11:57:43 AM ET 2010-05-10T15:57:43

BioDelivery Sciences International Inc. said Monday its cancer pain drug Onsolis received regulatory approval in Canada.

The drug, called BEMA Fentanyl and marketed as Onsolis, has already received approval in the U.S.

It will be marketed in Canada by Meda Valeant Pharma Canada Inc., a joint venture between BioDelivery's commercial partner, Meda AB, and Valeant Canada Ltd.

BioDelivery said the drug will be launched in Canada during the third quarter.

Shares of BioDelivery rose 8 cents, or 2.5 percent, to $3.24 in midday trading. The stock has traded between $3.10 and $8.29 over the last 52 weeks.

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.94%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.40%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.12%
17.11%
Source: Bankrate.com